Osteoarthrosis is the gradual breakdown of joint cartilage and the remodeling of surrounding bone that affects roughly 595 million people worldwide, or about 7.6% of the global population as of 2020. The term is often used interchangeably with “osteoarthritis,” though the “-osis” suffix more accurately reflects the condition’s degenerative nature rather than implying the primarily inflammatory process that “-itis” suggests. In practice, both terms describe the same disease, and the condition involves far more than simple “wear and tear” on cartilage. Changes to bone, synovial tissue, ligaments, and even the nervous system all play roles in how the disease progresses and how much pain it causes.
What Actually Happens Inside the Joint
The hallmark of osteoarthrosis is the progressive loss of articular cartilage, the smooth, rubbery tissue that caps the ends of bones where they meet. This breakdown is driven by enzymes that chew through the two main structural proteins holding cartilage together: aggrecan, which gives cartilage its ability to resist compression, and collagen, which provides its tensile strength. Research in transgenic mice has identified specific enzymes responsible, with ADAMTS-5 targeting aggrecan and MMP-13 targeting collagen as the principal culprits.
But the disease doesn’t stop at cartilage. The bone just beneath it, called subchondral bone, undergoes its own remodeling. Early on, this bone becomes more porous as resorption outpaces new bone formation. Later, the balance flips, and the bone thickens and hardens, a process visible on X-rays as subchondral sclerosis. Osteophytes, the bony spurs that are a classic radiographic sign, form along joint margins as part of the same remodeling process. These bone changes aren’t just bystanders. In animal models, drugs that blocked early subchondral bone resorption also reduced osteophyte formation and slowed cartilage loss in a dose-dependent manner, suggesting that what happens in bone actively drives what happens in cartilage above it.
Low-grade inflammation adds another layer. Although osteoarthrosis was long considered a purely mechanical disease, research now shows that inflammatory markers and immune mechanisms within the joint play a meaningful role. The inflammatory response involves both cells lining the joint and chondrocytes within the cartilage itself, and understanding these pathways has opened new possibilities for early detection and treatment.
Who Gets It and Why
No single cause explains osteoarthrosis. The disease emerges from a combination of mechanical, metabolic, and genetic factors that vary from person to person.
Excess body weight is one of the strongest and most modifiable risk factors, particularly for the knee. Higher body mass index is associated with significantly greater compressive forces through the knee joint during walking, independent of limb alignment. Obesity also damages joints through metabolic pathways, not just mechanical overload. Adipose tissue secretes inflammatory molecules that circulate throughout the body, reaching joints and promoting cartilage degradation even in non-weight-bearing joints like the hands.
Joint injuries, especially to the anterior cruciate ligament, are a potent trigger. Studies show that an ACL injury increases the risk of osteoarthrosis substantially, with symptomatic disease appearing in roughly half of affected individuals within 10 to 15 years. This happens regardless of whether the ligament is surgically reconstructed, because the initial trauma alters joint mechanics and triggers biological changes in the cartilage that persist long after the injury heals.
Genetics also plays a role, with heritability estimates for osteoarthrosis generally in the range of 40 to 65 percent depending on the joint. Several susceptibility genes have been identified, including NCOA3 and ALDH1A2, and the evidence points to disease risk being mediated primarily through changes in gene expression affecting cartilage maintenance and cell differentiation rather than through single dramatic mutations.
Limb alignment matters as well. Varus alignment, where the knees bow outward, concentrates force on the inner compartment of the knee and is associated with significantly higher external knee adduction moments during walking, independent of body weight. This mechanical maldistribution accelerates cartilage loss in the loaded compartment.
Why Pain Doesn’t Always Match the Damage
One of the most confusing aspects of osteoarthrosis, for patients and clinicians alike, is the weak link between what shows up on imaging and how much pain someone actually feels. Systematic reviews have found that among people with knee pain, the proportion who have radiographic osteoarthrosis ranges from 15 to 76 percent. Conversely, among people with radiographic disease, the proportion who report pain ranges from 15 to 81 percent. Some people with severely damaged joints feel relatively little discomfort, while others with mild radiographic changes are in considerable pain.
The explanation lies partly in pain sensitization. In osteoarthrosis, the nervous system itself changes. Peripheral nerve endings in the joint become hypersensitive to stimuli that would normally be painless, and over time, neurons in the spinal cord and brain amplify pain signals further through a process called central sensitization. A systematic review and meta-analysis confirmed that pain sensitization is present in people with knee osteoarthrosis and is associated with symptom severity. Inflammatory molecules like nerve growth factor and pro-inflammatory cytokines drive this sensitization, and they have become therapeutic targets in their own right.
This mismatch has practical consequences. It means that two patients with identical X-rays can have dramatically different experiences. It also means that treatments targeting only the structural damage will sometimes miss the mark if the nervous system’s pain-processing has changed. Addressing the neural component, whether through certain medications, exercise, or other approaches, can be just as important as addressing the joint itself.
How Osteoarthrosis Is Diagnosed and Tracked
Plain X-rays remain the standard first-line imaging tool. They reveal joint-space narrowing, osteophytes, subchondral sclerosis, and cysts. But X-rays only show bone and the space between bones; they cannot directly visualize cartilage, synovium, or early soft-tissue changes. MRI fills this gap. In longitudinal studies, changes in cartilage volume and thickness measured on MRI correlate with joint-space narrowing on X-ray, but MRI picks up abnormalities earlier and with greater sensitivity.
Blood and urine biomarkers are an active area of research. Urinary CTX-II, a fragment released when type II collagen breaks down, incrementally increases with higher radiographic severity and is independently associated with both disease severity and pain intensity. Another marker, COMP (cartilage oligomeric matrix protein), has shown predictive value for the progression of osteophytes. In a follow-up study over six years, every unit increase in COMP level was associated with a 33 percent higher risk of osteophyte progression in the knee. These markers aren’t yet routine in clinical practice, but they may eventually help identify patients whose disease is progressing before X-rays show obvious worsening.
Exercise, Weight Loss, and the First Line of Defense
Exercise is consistently recommended as a cornerstone of osteoarthrosis management, and quadriceps strengthening in particular has strong evidence behind it. A systematized review of randomized controlled trials found that quadriceps strengthening significantly reduced pain and improved function in knee osteoarthrosis, with effective routines including straight leg raises, terminal knee extensions, and both open and closed chain movements performed over 8 to 12 weeks. The benefits extend beyond the muscle itself: stronger quadriceps stabilize the knee, absorb shock during walking, and reduce the load transmitted through damaged cartilage.
Weight loss delivers both mechanical and biochemical payoffs. Losing weight reduces the compressive forces passing through the knee with every step, and it also dials down systemic inflammation. A loss of body fat can reduce circulating levels of inflammatory cytokines like IL-6 by roughly 25 to 30 percent. In patients with obesity-related knee osteoarthrosis who underwent bariatric surgery, the results were striking: knee pain dropped substantially, all functional scores improved, and biomarkers shifted in a favorable direction. A marker of cartilage synthesis rose by 32 percent, while COMP, the cartilage-degradation marker, fell by 36 percent. These biochemical changes suggest that weight loss doesn’t just relieve symptoms; it may slow or partially reverse the destructive processes in the joint.
The combination of exercise and weight management works better than either alone. Both approaches address the mechanical and inflammatory contributors to disease simultaneously, and neither carries the risks associated with long-term medication use or surgery.
Injections and Their Time Courses
When oral painkillers and lifestyle changes aren’t enough, joint injections are a common next step. The two most widely used injectables for knee osteoarthrosis are corticosteroids and hyaluronic acid, and they have distinctly different time profiles.
Corticosteroid injections work fast. They provide superior pain relief in the first month compared to hyaluronic acid. But their effect fades. By three months, the two are roughly equivalent. By six months, hyaluronic acid pulls ahead, delivering greater pain reduction and functional improvement. A meta-analysis found that this crossover pattern held consistently across studies, with the effect size at 26 weeks favoring hyaluronic acid. This means corticosteroids are best suited for short-term flare management, while hyaluronic acid may be the better choice when longer-lasting relief is the goal, though neither is a permanent solution.
There are caveats. Repeated corticosteroid injections over time may accelerate cartilage loss in some patients, a concern that has led many clinicians to limit their frequency. Hyaluronic acid, while generally safe, has more variable results across studies, and some trials have found it to be only modestly better than saline placebo. The response to either injection varies considerably from person to person.
Nerve Ablation for Persistent Pain
For patients who have exhausted conservative options and are either not candidates for joint replacement or want to delay it, genicular nerve radiofrequency ablation has emerged as an intermediate option. The procedure uses heat to disrupt the small sensory nerves around the knee that transmit pain signals. It doesn’t treat the underlying disease, but it can meaningfully reduce the pain it causes.
In a study of cooled radiofrequency ablation, average pain scores dropped by 50 percent at two weeks and 55 percent at four to six weeks. The effect began to diminish further out, with a 26 percent reduction at later follow-up, and the mean duration of meaningful relief was about nine months. The procedure is repeatable, which matters because the nerves eventually regenerate. It’s typically reserved for patients who have failed conservative treatment and have had a positive response to a diagnostic nerve block.
Joint Replacement and What to Expect
Total knee arthroplasty remains the definitive treatment for advanced osteoarthrosis that hasn’t responded to other approaches. The outcomes in most patients are good. A recent meta-analysis of total knee replacements in patients under 50 found survivorship rates of 97 percent at less than five years, 95 percent at five to ten years, and 87 percent beyond ten years. Mean postoperative range of motion was about 121 degrees, and functional scores were substantially improved.
For younger patients, the math is more complicated. Implants don’t last forever, and the younger you are at surgery, the more likely you are to need a revision. Longer-term data from longitudinal studies show survivorship dropping to roughly 70 percent at 30 years and 52 to 65 percent at 40 years. Aseptic loosening, where the implant gradually detaches from the bone without infection being involved, is the most common reason for revision. This is why orthopedic surgeons often encourage younger patients to exhaust every non-surgical option first: the goal is to buy time so that the first replacement lasts as long as possible.
The Search for Disease-Modifying Drugs
Every treatment discussed so far manages symptoms or replaces the damaged joint. None reverses or halts the underlying disease process. The search for disease-modifying osteoarthritis drugs, or DMOADs, has been one of the most active and frustrating areas in rheumatology research. A review of clinical trials from 2010 to 2024 identified eleven DMOAD candidates that have reached clinical testing, including drugs targeting Wnt signaling, cartilage growth factors, inflammatory cytokines, and enzymes involved in cartilage breakdown. Of these, six showed statistically significant evidence of structural or symptomatic benefit without major safety concerns in phase II and III randomized controlled trials. Sprifermin, a fibroblast growth factor that stimulates cartilage growth, is among the most closely watched. But translating promising trial results into approved medications has been slow, partly because the disease progresses over years and clinical trials struggle to demonstrate meaningful structural change in short timeframes.
Stem cell therapies represent another frontier. Mesenchymal stem cells have shown promise in both preclinical experiments and early clinical trials for cartilage repair. However, large-scale clinical application has been hampered by challenges in producing cells at scale, keeping them viable in the hostile environment of a diseased joint, and achieving consistent therapeutic effects. Researchers are exploring hydrogel delivery systems to protect transplanted cells and improve their survival, and exosome-based therapies that use the signaling molecules secreted by stem cells rather than the cells themselves.
The Global Weight of the Disease
Osteoarthrosis is among the most common chronic conditions on Earth. Total cases increased by 132 percent between 1990 and 2020, driven by population aging and rising obesity rates. It ranks as the 15th highest cause of years lived with disability worldwide, and the economic toll is enormous, ranging from 1 to 2.5 percent of gross national product in countries with established market economies. The average annual cost for an individual with the condition is estimated between $700 and $15,600, a range that reflects vast differences in healthcare systems, disease severity, and access to treatment.
Projections to 2050 suggest the burden will continue growing. As populations in low- and middle-income countries age and obesity becomes more prevalent globally, the number of people living with osteoarthrosis is expected to rise sharply, placing increasing pressure on health systems that are already strained.
Circadian Rhythms and Joint Health
An unexpected line of research has linked disrupted circadian rhythms to osteoarthrosis. Experimental studies indicate that circadian dysregulation in joint tissues can alter chondrocyte metabolism, the turnover of cartilage matrix, inflammatory activity in the synovium, and subchondral bone remodeling. In people, disturbed sleep and circadian misalignment are associated with greater osteoarthrosis symptom burden, though direct causal evidence in humans remains limited.
The relationship appears to run in both directions. Osteoarthrosis-related pain disrupts sleep, which worsens circadian alignment, which in turn may accelerate joint deterioration and amplify pain perception, creating a self-reinforcing cycle. While nobody is suggesting that better sleep will cure osteoarthrosis, optimizing sleep quality and maintaining consistent sleep-wake schedules may be an underappreciated component of managing the condition, particularly given what we know about pain sensitization and its neural drivers.
An Evolutionary Mismatch
Osteoarthrosis is sometimes dismissed as an inevitable consequence of aging, but comparative data tell a more nuanced story. Studies comparing joint disease in African great apes and humans found that all apes display significantly less spinal disease than comparable human samples, differences most likely explained by human biomechanical adaptations for bipedal locomotion. Apes are also generally less affected in major peripheral joints than humans are, though human populations themselves are highly variable in their prevalence of peripheral osteoarthrosis.
Walking upright redistributed mechanical loads across the skeleton in ways that made certain joints, particularly the knee and hip, bear forces they were not optimally designed for over a full modern lifespan. Couple that with the fact that humans now live decades longer than our ancestors typically did, carry more body weight, and often perform repetitive occupational tasks, and the high prevalence of osteoarthrosis starts to look less like an inevitability of biology and more like a mismatch between our evolved anatomy and the way we use it today.